title: Therapeutically Induced Changes in HER2, HER3, and EGFR Protein Expression for Treatment Guidance.
abstract: Protein-targeted therapies are expected to selectively kill tumor cells that express the targeted protein biomarker. Although a tumor mass may initially respond to targeted therapies based on expression of the targeted protein, all cells within a tumor may not express the targeted protein above a critical threshold level; therefore, those cells that do not express, or that downregulate expression of, the targeted protein may not be responsive to therapy. The ability to monitor the dynamic expression of these protein biomarkers throughout the course of therapy may allow for treatment to be personalized in real-time in response to the evolving nature of the tumor. This report demonstrates, by monitoring a single patient through multiple therapies, how targeted mass spectrometry is an effective, quantitative method that provides real-time analysis of multiple therapeutically associated targeted proteins that can be used to personalize a patient's treatment strategy throughout the course of care.
authors.affiliation: NantOmics, LLC, Rockville, Maryland
authors.forename: Shankar
authors.initials: S
authors.lastname: Sellappan
authors.affiliation: NantOmics, LLC, Rockville, Maryland
authors.forename: Adele
authors.initials: A
authors.lastname: Blackler
authors.affiliation: NantOmics, LLC, Rockville, Maryland
authors.forename: Wei-Li
authors.initials: WL
authors.lastname: Liao
authors.affiliation: University of Chicago, Department of Medicine, Section of Hematology & Oncology, Chicago, Illinois
authors.forename: Emily
authors.initials: E
authors.lastname: O'Day
authors.affiliation: University of Chicago, Department of Medicine, Section of Hematology & Oncology, Chicago, Illinois
authors.forename: Peng
authors.initials: P
authors.lastname: Xu
authors.affiliation: NantOmics, LLC, Rockville, Maryland
authors.forename: Sheeno
authors.initials: S
authors.lastname: Thyparambil
authors.affiliation: NantOmics, LLC, Rockville, Maryland
authors.forename: Fabiola
authors.initials: F
authors.lastname: Cecchi
authors.affiliation: NantOmics, LLC, Rockville, Maryland
authors.forename: Todd
authors.initials: T
authors.lastname: Hembrough
authors.affiliation: University of Chicago, Department of Medicine, Section of Hematology & Oncology, Chicago, Illinois
authors.forename: Daniel V T
authors.initials: DV
authors.lastname: Catenacci
mesh_terms: D000328:Adult; D049109:Cell Proliferation; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D008297:Male; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction; D016896:Treatment Outcome
chemical_list: D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases